Faron Pharmaceuticals' Bexmarilimab shows 50% remission rate

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical company - Says Bexmarilimab study shows 50% remission rate for patients with in relapsed/refractory acute myeloid...

Related Keywords

Finland ,Markku Jalkanen ,Alliance News ,Alliance News Ltd ,Faron Pharmaceuticals Ltd ,Executive Officer Markku Jalkanen ,Sabrina Penty ,All Rights ,Markets ,